Tony Ton

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 430 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld, Timothy D. Owens, Erik Verner et al. · Journal of Medicinal Chemistry · 2017 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Timothy D. Owens, Ken A. Brameld, Erik Verner et al. · Journal of Medicinal Chemistry · 2022 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of novel heterocyclic factor VIIa inhibitors

Roopa Rai, Aleksandr Kolesnikov, Paul A. Sprengeler et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 26 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Factor VIIa inhibitors: Gaining selectivity within the trypsin family

William D. Shrader, Aleksandr Kolesnikov, Jana Burgess‐Henry et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +7